Cargando…
KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease. Since the discovery of KSHV 20 years ago, there is still no standard treatment and the management of virus-associated malignancies remains toxic...
Autores principales: | Coen, Natacha, Duraffour, Sophie, Snoeck, Robert, Andrei, Graciela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246246/ https://www.ncbi.nlm.nih.gov/pubmed/25421895 http://dx.doi.org/10.3390/v6114731 |
Ejemplares similares
-
RSK1 SUMOylation is required for KSHV lytic replication
por: Liu, Zhenshan, et al.
Publicado: (2021) -
Lytic viral replication and immunopathology in a cytomegalovirus-induced mouse model of secondary hemophagocytic lymphohistiocytosis
por: Brisse, Ellen, et al.
Publicado: (2017) -
Activation of DNA Damage Response Pathways during Lytic Replication of KSHV
por: Hollingworth, Robert, et al.
Publicado: (2015) -
Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication
por: Park, Mi-Kyung, et al.
Publicado: (2019) -
Molecular Biology of KSHV Lytic Reactivation
por: Purushothaman, Pravinkumar, et al.
Publicado: (2015)